-
1
-
-
34547631086
-
-
online, Available from URL:, Accessed 2009 Apr 29
-
UNAIDS/WHO. Global AIDS epidemic continues to grow 2006 [online]. Available from URL: http://www.who.int/hiv/mediacentre/news62/en/index. html [Accessed 2009 Apr 29]
-
(2006)
Global AIDS epidemic continues to grow
-
-
-
2
-
-
13944254982
-
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection
-
Mar 1;
-
Flynn NM, Forthal DN, Harro CD,et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005 Mar 1; 191 (5): 654-65
-
(2005)
J Infect Dis
, vol.191
, Issue.5
, pp. 654-665
-
-
Flynn, N.M.1
Forthal, D.N.2
Harro, C.D.3
-
3
-
-
33845433434
-
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
-
Dec 15;
-
Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006 Dec 15; 194 (12): 1661-71
-
(2006)
J Infect Dis
, vol.194
, Issue.12
, pp. 1661-1671
-
-
Pitisuttithum, P.1
Gilbert, P.2
Gurwith, M.3
-
4
-
-
56649105122
-
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial
-
Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-93
-
(2008)
Lancet
, vol.372
, pp. 1881-1893
-
-
Buchbinder, S.P.1
Mehrotra, D.V.2
Duerr, A.3
-
5
-
-
0028041344
-
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
-
Sep;
-
Borrow P, Lewicki H, Hahn BH, et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994 Sep; 68 (9): 6103-10
-
(1994)
J Virol
, vol.68
, Issue.9
, pp. 6103-6110
-
-
Borrow, P.1
Lewicki, H.2
Hahn, B.H.3
-
6
-
-
0028337166
-
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
-
Jul;
-
Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994 Jul; 68 (7): 4650-5
-
(1994)
J Virol
, vol.68
, Issue.7
, pp. 4650-4655
-
-
Koup, R.A.1
Safrit, J.T.2
Cao, Y.3
-
7
-
-
0033524838
-
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
-
Feb 5;
-
Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999 Feb 5; 283 (5403): 857-60
-
(1999)
Science
, vol.283
, Issue.5403
, pp. 857-860
-
-
Schmitz, J.E.1
Kuroda, M.J.2
Santra, S.3
-
8
-
-
0032512004
-
HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons
-
Nov 12;
-
Bernard NF, Pederson K, Chung F, et al. HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons. AIDS 1998 Nov 12; 12 (16): 2125-39
-
(1998)
AIDS
, vol.12
, Issue.16
, pp. 2125-2139
-
-
Bernard, N.F.1
Pederson, K.2
Chung, F.3
-
9
-
-
0031664158
-
Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: A predominant gag-specific response is associated with non-progressive infection
-
Oct;
-
Pontesilli O, Klein MR, Kerkhof-Garde SR, et al. Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with non-progressive infection. J Infect Dis 1998 Oct; 178 (4): 1008-18
-
(1998)
J Infect Dis
, vol.178
, Issue.4
, pp. 1008-1018
-
-
Pontesilli, O.1
Klein, M.R.2
Kerkhof-Garde, S.R.3
-
10
-
-
0035815437
-
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
-
Apr 6;
-
Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001 Apr 6; 292 (5514): 69-74
-
(2001)
Science
, vol.292
, Issue.5514
, pp. 69-74
-
-
Amara, R.R.1
Villinger, F.2
Altman, J.D.3
-
11
-
-
0037122719
-
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
-
Jan 17;
-
Shiver JW, FuTM, ChenL,etal. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002 Jan 17; 415 (6869): 331-5
-
(2002)
Nature
, vol.415
, Issue.6869
, pp. 331-335
-
-
Shiver, J.W.1
Fu, T.M.2
Chen, L.3
-
12
-
-
0033766645
-
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augumented DNA vaccination
-
Oct 20;
-
Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augumented DNA vaccination. Science 2000 Oct 20; 290: 486-92
-
(2000)
Science
, vol.290
, pp. 486-492
-
-
Barouch, D.H.1
Santra, S.2
Schmitz, J.E.3
-
13
-
-
29244455769
-
Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag
-
Casimiro D, Wang F, Schleif W, et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol 2005; 79 (24): 15547-55
-
(2005)
J Virol
, vol.79
, Issue.24
, pp. 15547-15555
-
-
Casimiro, D.1
Wang, F.2
Schleif, W.3
-
14
-
-
25144485385
-
Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesusmonkeys
-
Oct;
-
Liang X, Casimiro DR, Schleif WA, et al. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesusmonkeys. JVirol 2005 Oct;79(19): 12321-31
-
(2005)
JVirol
, vol.79
, Issue.19
, pp. 12321-12331
-
-
Liang, X.1
Casimiro, D.R.2
Schleif, W.A.3
-
15
-
-
35748968205
-
-
HIV vaccine failure prompts Merck to halt trial. Nature 2007 Sep 27; 449 (7161): 390
-
HIV vaccine failure prompts Merck to halt trial. Nature 2007 Sep 27; 449 (7161): 390
-
-
-
-
16
-
-
37549033167
-
One step forward, two steps back: Will there ever be an AIDS vaccine?
-
Dec 27;
-
Steinbrook R. One step forward, two steps back: will there ever be an AIDS vaccine? N Engl J Med 2007 Dec 27; 357 (26): 2653-5
-
(2007)
N Engl J Med
, vol.357
, Issue.26
, pp. 2653-2655
-
-
Steinbrook, R.1
-
17
-
-
38349151669
-
HIV-1 T-cell vaccines: Evaluating the next step
-
Feb;
-
Pantaleo G. HIV-1 T-cell vaccines: evaluating the next step. Lancet Infect Dis 2008 Feb; 8 (2): 82-3
-
(2008)
Lancet Infect Dis
, vol.8
, Issue.2
, pp. 82-83
-
-
Pantaleo, G.1
-
18
-
-
36248941489
-
HIV vaccine may raise risk
-
Nov 15;
-
Ledford H. HIV vaccine may raise risk. Nature 2007 Nov 15; 450 (7168): 325
-
(2007)
Nature
, vol.450
, Issue.7168
, pp. 325
-
-
Ledford, H.1
-
19
-
-
0035162494
-
Evolutionary and immunological implications of contemporary HIV-1 variation
-
Korber B, Gaschen B, Yusim K, et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001; 58: 19-42
-
(2001)
Br Med Bull
, vol.58
, pp. 19-42
-
-
Korber, B.1
Gaschen, B.2
Yusim, K.3
-
20
-
-
33646146379
-
GP120: Target for neutralizing HIV-1 antibodies
-
Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 2006; 24: 739-69
-
(2006)
Annu Rev Immunol
, vol.24
, pp. 739-769
-
-
Pantophlet, R.1
Burton, D.R.2
-
22
-
-
9544239346
-
The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate
-
Oct;
-
Conley AJ, Kessler II JA, Boots LJ, et al. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J Virol 1996 Oct; 70 (10): 6751-8
-
(1996)
J Virol
, vol.70
, Issue.10
, pp. 6751-6758
-
-
Conley, A.J.1
Kessler II, J.A.2
Boots, L.J.3
-
23
-
-
0026557112
-
Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
-
Feb 20;
-
Emini EA, Schleif WA, Nunberg JH, et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992 Feb 20; 355 (6362): 728-30
-
(1992)
Nature
, vol.355
, Issue.6362
, pp. 728-730
-
-
Emini, E.A.1
Schleif, W.A.2
Nunberg, J.H.3
-
24
-
-
0036307928
-
Postnatal pre- and postexposure passive immunization strategies: Protection of neonatal macaques against oral simian-human immunodeficiency virus challenge
-
Jun;
-
Hofmann-Lehmann R, Vlasak J, Rasmussen RA, et al. Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. J Med Primatol 2002 Jun; 31 (3): 109-19
-
(2002)
J Med Primatol
, vol.31
, Issue.3
, pp. 109-119
-
-
Hofmann-Lehmann, R.1
Vlasak, J.2
Rasmussen, R.A.3
-
25
-
-
0034904087
-
Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge
-
Aug;
-
Hofmann-Lehmann R, Vlasak J, Rasmussen RA, et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol 2001 Aug; 75 (16): 7470-80
-
(2001)
J Virol
, vol.75
, Issue.16
, pp. 7470-7480
-
-
Hofmann-Lehmann, R.1
Vlasak, J.2
Rasmussen, R.A.3
-
26
-
-
0032947286
-
Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
-
May;
-
Mascola JR, Lewis MG, Stiegler G, et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999 May; 73 (5): 4009-18
-
(1999)
J Virol
, vol.73
, Issue.5
, pp. 4009-4018
-
-
Mascola, J.R.1
Lewis, M.G.2
Stiegler, G.3
-
27
-
-
0033951746
-
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virusby passive infusion of neutralizing antibodies
-
Feb;
-
Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virusby passive infusion of neutralizing antibodies. Nat Med 2000 Feb;6 (2): 207-10
-
(2000)
Nat Med
, vol.6
, Issue.2
, pp. 207-210
-
-
Mascola, J.R.1
Stiegler, G.2
VanCott, T.C.3
-
28
-
-
0025331727
-
Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
-
Jun 14;
-
Berman PW, Gregory TJ, Riddle L, et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990 Jun 14; 345 (6276): 622-5
-
(1990)
Nature
, vol.345
, Issue.6276
, pp. 622-625
-
-
Berman, P.W.1
Gregory, T.J.2
Riddle, L.3
-
29
-
-
0028892847
-
Resistance of chimpanzees immunized with recombinant gp120SF2to challenge byHIV-1SF2
-
Dec;
-
el-Amad Z, Murthy KK, Higgins K, et al. Resistance of chimpanzees immunized with recombinant gp120SF2to challenge byHIV-1SF2. AIDS 1995 Dec; 9 (12): 1313-22
-
(1995)
AIDS
, vol.9
, Issue.12
, pp. 1313-1322
-
-
el-Amad, Z.1
Murthy, K.K.2
Higgins, K.3
-
30
-
-
19144370387
-
Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1
-
Jan;
-
Berman PW, Murthy KK, Wrin T, et al. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J Infect Dis 1996 Jan; 173 (1): 52-9
-
(1996)
J Infect Dis
, vol.173
, Issue.1
, pp. 52-59
-
-
Berman, P.W.1
Murthy, K.K.2
Wrin, T.3
-
31
-
-
0027178289
-
Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine
-
Jul 10;
-
Schwartz DH, Gorse G, Clements ML, et al. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine. Lancet 1993 Jul 10; 342 (8863): 69-73
-
(1993)
Lancet
, vol.342
, Issue.8863
, pp. 69-73
-
-
Schwartz, D.H.1
Gorse, G.2
Clements, M.L.3
-
32
-
-
0027430975
-
Safety and immunogenicity of afully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network
-
Dec;
-
Belshe RB, Clements ML, Dolin R, etal. Safety and immunogenicity of afully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. J Infect Dis 1993 Dec; 168 (6): 1387-95
-
(1993)
J Infect Dis
, vol.168
, Issue.6
, pp. 1387-1395
-
-
Belshe, R.B.1
Clements, M.L.2
Dolin, R.3
-
33
-
-
0028024901
-
Neutralizing antibodiestoHIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain ofHIV-1. NIAID AIDS Vaccine Clinical TrialsNetwork
-
Aug 10;
-
Belshe RB, Graham BS, Keefer MC,et al. Neutralizing antibodiestoHIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain ofHIV-1. NIAID AIDS Vaccine Clinical TrialsNetwork. JAMA 1994 Aug 10; 272 (6): 475-80
-
(1994)
JAMA
, vol.272
, Issue.6
, pp. 475-480
-
-
Belshe, R.B.1
Graham, B.S.2
Keefer, M.C.3
-
34
-
-
0030586434
-
Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120: a randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group
-
Aug 15;
-
Graham BS, Keefer MC, McElrath MJ, et al. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120: a randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Ann Intern Med 1996 Aug 15; 125 (4): 270-9
-
(1996)
Ann Intern Med
, vol.125
, Issue.4
, pp. 270-279
-
-
Graham, B.S.1
Keefer, M.C.2
McElrath, M.J.3
-
35
-
-
4444309788
-
Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1
-
Sep 1;
-
Pitisuttithum P, Berman PW, Phonrat B, et al. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J Acquir Immune Defic Syndr 2004 Sep 1; 37 (1): 1160-5
-
(2004)
J Acquir Immune Defic Syndr
, vol.37
, Issue.1
, pp. 1160-1165
-
-
Pitisuttithum, P.1
Berman, P.W.2
Phonrat, B.3
-
36
-
-
0031763443
-
Advancing AIDSVAX to phase 3: Safety, immunogenicity, and plans for phase 3
-
Oct;
-
Francis DP, Gregory T, McElrath MJ, et al. Advancing AIDSVAX to phase 3: safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses 1998 Oct; 14 Suppl. 3: S325-31
-
(1998)
AIDS Res Hum Retroviruses
, vol.14
, Issue.SUPPL. 3
-
-
Francis, D.P.1
Gregory, T.2
McElrath, M.J.3
-
37
-
-
13944250922
-
Correlation between im-munologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial
-
Mar 1;
-
Gilbert PB, Peterson ML, Follmann D, et al. Correlation between im-munologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005 Mar 1; 191 (5): 666-77
-
(2005)
J Infect Dis
, vol.191
, Issue.5
, pp. 666-677
-
-
Gilbert, P.B.1
Peterson, M.L.2
Follmann, D.3
-
38
-
-
19944427052
-
-
Gao F, Weaver EA, Lu Z, et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group M consensus envelope glycoprotein. J Virol 2005 Jan 2005; 79 (2): 1154-63
-
Gao F, Weaver EA, Lu Z, et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group M consensus envelope glycoprotein. J Virol 2005 Jan 2005; 79 (2): 1154-63
-
-
-
-
39
-
-
33746689169
-
A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses
-
Sep 30;
-
Liao HX, Sutherland LL, Xia SM, et al. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 2006 Sep 30; 353 (2): 268-82
-
(2006)
Virology
, vol.353
, Issue.2
, pp. 268-282
-
-
Liao, H.X.1
Sutherland, L.L.2
Xia, S.M.3
-
40
-
-
33847266930
-
Antigenicity and immunogenicityofHIV-1 consensus subtype B envelope glycoproteins
-
Mar 30;
-
Kothe DL, Decker JM, LiY,et al. Antigenicity and immunogenicityofHIV-1 consensus subtype B envelope glycoproteins. Virology 2007 Mar 30; 360 (1): 218-34
-
(2007)
Virology
, vol.360
, Issue.1
, pp. 218-234
-
-
Kothe, D.L.1
Decker, J.M.2
LiY3
-
41
-
-
33747041588
-
Ancestral and consensus envelope im-munogens for HIV-1 subtype C
-
Sep 1;
-
Kothe DL, Li Y, Decker JM, et al. Ancestral and consensus envelope im-munogens for HIV-1 subtype C. Virology 2006 Sep 1; 352 (2): 438-49
-
(2006)
Virology
, vol.352
, Issue.2
, pp. 438-449
-
-
Kothe, D.L.1
Li, Y.2
Decker, J.M.3
-
42
-
-
23844468382
-
Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope
-
Sep;
-
Doria-Rose NA, Learn GH, Rodrigo AG, et al. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J Virol 2005 Sep; 79 (17): 11214-24
-
(2005)
J Virol
, vol.79
, Issue.17
, pp. 11214-11224
-
-
Doria-Rose, N.A.1
Learn, G.H.2
Rodrigo, A.G.3
-
43
-
-
0031906852
-
Immunogenicity of DNA vaccines expressing human immunodeficiency virus type1envelope glycoprotein with and without deletions in the V1/2 and V3 regions
-
Lu S, Wyatt R, Richmond JF, et al. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type1envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res Hum Retroviruses 1998; 14 (2): 151-5
-
(1998)
AIDS Res Hum Retroviruses
, vol.14
, Issue.2
, pp. 151-155
-
-
Lu, S.1
Wyatt, R.2
Richmond, J.F.3
-
44
-
-
33748650781
-
Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: Comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection
-
Sep;
-
Derby NR, Kraft Z, Kan E, et al. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J Virol 2006 Sep; 80 (17): 8745-62
-
(2006)
J Virol
, vol.80
, Issue.17
, pp. 8745-8762
-
-
Derby, N.R.1
Kraft, Z.2
Kan, E.3
-
45
-
-
0037225248
-
Immunogenicity and ability of variable loopdeleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies
-
Jan 5;
-
Kim YB, Han DP, Cao C, et al. Immunogenicity and ability of variable loopdeleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies. Virology 2003 Jan 5; 305 (1): 124-37
-
(2003)
Virology
, vol.305
, Issue.1
, pp. 124-137
-
-
Kim, Y.B.1
Han, D.P.2
Cao, C.3
-
46
-
-
0035000679
-
The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
-
Jun;
-
Barnett SW, Lu S, Srivastava I, et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 2001 Jun; 75 (12): 5526-40
-
(2001)
J Virol
, vol.75
, Issue.12
, pp. 5526-5540
-
-
Barnett, S.W.1
Lu, S.2
Srivastava, I.3
-
47
-
-
27144524041
-
Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain
-
Nov;
-
Lian Y, Srivastava I, Gomez-Roman VR, et al. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J Virol 2005 Nov; 79 (21): 13338-49
-
(2005)
J Virol
, vol.79
, Issue.21
, pp. 13338-13349
-
-
Lian, Y.1
Srivastava, I.2
Gomez-Roman, V.R.3
-
48
-
-
0141788494
-
Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate
-
Oct;
-
Srivastava IK, Stamatatos L, Kan E, et al. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J Virol 2003 Oct; 77 (20): 11244-59
-
(2003)
J Virol
, vol.77
, Issue.20
, pp. 11244-11259
-
-
Srivastava, I.K.1
Stamatatos, L.2
Kan, E.3
-
49
-
-
25144477447
-
Comparing antigenicity and immunogenicity of engineered gp120
-
Oct;
-
Selvarajah S, Puffer B, Pantophlet R, et al. Comparing antigenicity and immunogenicity of engineered gp120. J Virol 2005 Oct; 79 (19): 12148-63
-
(2005)
J Virol
, vol.79
, Issue.19
, pp. 12148-12163
-
-
Selvarajah, S.1
Puffer, B.2
Pantophlet, R.3
-
50
-
-
39549097297
-
Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140
-
Feb;
-
Selvarajah S, Puffer BA, Lee FH, et al. Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140. AIDS Res Hum Retroviruses 2008 Feb; 24 (2): 301-14
-
(2008)
AIDS Res Hum Retroviruses
, vol.24
, Issue.2
, pp. 301-314
-
-
Selvarajah, S.1
Puffer, B.A.2
Lee, F.H.3
-
51
-
-
0031749469
-
A role for carbohydrates in immune evasion in AIDS
-
Jun;
-
Reitter JN, Means RE, Desrosiers RC. A role for carbohydrates in immune evasion in AIDS. Nat Med 1998 Jun; 4 (6): 679-84
-
(1998)
Nat Med
, vol.4
, Issue.6
, pp. 679-684
-
-
Reitter, J.N.1
Means, R.E.2
Desrosiers, R.C.3
-
52
-
-
37849026069
-
Removal of a single N-linked glycan in human immunodeficiency virus type1 gp120 results in anenhanced ability to induce neutralizing antibody responses
-
Jan;
-
Li Y, Cleveland B, Klots I, et al. Removal of a single N-linked glycan in human immunodeficiency virus type1 gp120 results in anenhanced ability to induce neutralizing antibody responses. J Virol 2008 Jan; 82 (2): 638-51
-
(2008)
J Virol
, vol.82
, Issue.2
, pp. 638-651
-
-
Li, Y.1
Cleveland, B.2
Klots, I.3
-
53
-
-
0030016341
-
Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response
-
Jul;
-
Bolmstedt A, Sjolander S, Hansen JE, et al. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. J Acquir Immune Defic Syndr Hum Retrovirol 1996 Jul; 12 (3): 213-20
-
(1996)
J Acquir Immune Defic Syndr Hum Retrovirol
, vol.12
, Issue.3
, pp. 213-220
-
-
Bolmstedt, A.1
Sjolander, S.2
Hansen, J.E.3
-
54
-
-
0036229473
-
Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: Effects on protein function and the neutralizing antibody response
-
May;
-
Quinones-Kochs MI, Buonocore L, Rose JK. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J Virol 2002 May; 76 (9): 4199-211
-
(2002)
J Virol
, vol.76
, Issue.9
, pp. 4199-4211
-
-
Quinones-Kochs, M.I.1
Buonocore, L.2
Rose, J.K.3
-
55
-
-
0035168058
-
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140
-
Jan;
-
Earl PL, Sugiura W, Montefiori DC, et al. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol 2001 Jan; 75 (2): 645-53
-
(2001)
J Virol
, vol.75
, Issue.2
, pp. 645-653
-
-
Earl, P.L.1
Sugiura, W.2
Montefiori, D.C.3
-
56
-
-
34547154404
-
Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization
-
Jun 12;
-
Zhang PF, Cham F, Dong M, et al. Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc Natl Acad Sci U S A 2007 Jun 12; 104 (24): 10193-8
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, Issue.24
, pp. 10193-10198
-
-
Zhang, P.F.1
Cham, F.2
Dong, M.3
-
57
-
-
21644445378
-
Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1
-
Jul;
-
Beddows S, Schulke N, Kirschner M, et al. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2005 Jul; 79 (14): 8812-27
-
(2005)
J Virol
, vol.79
, Issue.14
, pp. 8812-8827
-
-
Beddows, S.1
Schulke, N.2
Kirschner, M.3
-
58
-
-
0035155850
-
Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers
-
Feb;
-
Yang X, Wyatt R, Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 2001 Feb; 75 (3): 1165-71
-
(2001)
J Virol
, vol.75
, Issue.3
, pp. 1165-1171
-
-
Yang, X.1
Wyatt, R.2
Sodroski, J.3
-
59
-
-
31144451337
-
Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants
-
Feb;
-
Li Y, Svehla K, Mathy NL, et al. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol 2006 Feb; 80 (3): 1414-26
-
(2006)
J Virol
, vol.80
, Issue.3
, pp. 1414-1426
-
-
Li, Y.1
Svehla, K.2
Mathy, N.L.3
-
60
-
-
34249827906
-
Characterization of human immunodeficiency virus type1monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: Antigenicity, biophysics, and immunogenicity
-
Jun;
-
Dey B, Pancera M, Svehla K, et al. Characterization of human immunodeficiency virus type1monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J Virol 2007 Jun; 81 (11): 5579-93
-
(2007)
J Virol
, vol.81
, Issue.11
, pp. 5579-5593
-
-
Dey, B.1
Pancera, M.2
Svehla, K.3
-
61
-
-
0033575483
-
Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein
-
Liang X, Munshi S, Shendure J, et al. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. Vaccine 1999; 17: 2862-72
-
(1999)
Vaccine
, vol.17
, pp. 2862-2872
-
-
Liang, X.1
Munshi, S.2
Shendure, J.3
-
62
-
-
34247166722
-
-
Law M, Cardoso RM, Wilson IA, et al. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy.JVirol 2007 Apr; 81(8): 4272-85
-
Law M, Cardoso RM, Wilson IA, et al. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy.JVirol 2007 Apr; 81(8): 4272-85
-
-
-
-
63
-
-
23244467373
-
Recommendations for the design and use ofstandard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines
-
Aug;
-
Mascola JR, D'Souza P, GilbertP,et al. Recommendations for the design and use ofstandard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 2005 Aug; 79 (16): 10103-7
-
(2005)
J Virol
, vol.79
, Issue.16
, pp. 10103-10107
-
-
Mascola, J.R.1
D'Souza, P.2
GilbertP3
-
64
-
-
23244434512
-
Human immunodeficiency virus type 1 Env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
-
Aug;
-
Li M, Gao F, Mascola JR, et al. Human immunodeficiency virus type 1 Env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005 Aug; 79 (16): 10108-25
-
(2005)
J Virol
, vol.79
, Issue.16
, pp. 10108-10125
-
-
Li, M.1
Gao, F.2
Mascola, J.R.3
-
65
-
-
0031666180
-
An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades
-
Oct;
-
Stamatatos L, Cheng-Mayer C. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. J Virol 1998 Oct; 72 (10): 7840-5
-
(1998)
J Virol
, vol.72
, Issue.10
, pp. 7840-7845
-
-
Stamatatos, L.1
Cheng-Mayer, C.2
-
66
-
-
2342644898
-
The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection
-
May;
-
Pinter A, Honnen WJ, He Y, et al. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 2004 May; 78 (10): 5205-15
-
(2004)
J Virol
, vol.78
, Issue.10
, pp. 5205-5215
-
-
Pinter, A.1
Honnen, W.J.2
He, Y.3
-
67
-
-
0141458878
-
Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities
-
Sep;
-
Johnson WE, Sanford H, Schwall L, et al. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J Virol 2003 Sep; 77 (18): 9993-10003
-
(2003)
J Virol
, vol.77
, Issue.18
, pp. 9993-10003
-
-
Johnson, W.E.1
Sanford, H.2
Schwall, L.3
-
68
-
-
0030812563
-
Replication and neutralizationof human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein
-
Dec;
-
Cao J,Sullivan N, Desjardin E,et al. Replication and neutralizationof human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol 1997 Dec; 71 (12): 9808-12
-
(1997)
J Virol
, vol.71
, Issue.12
, pp. 9808-9812
-
-
Cao, J.1
Sullivan, N.2
Desjardin, E.3
-
69
-
-
0037321708
-
Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region
-
Feb;
-
Srivastava IK, VanDorsten K, Vojtech L, et al. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol 2003 Feb; 77 (4): 2310-20
-
(2003)
J Virol
, vol.77
, Issue.4
, pp. 2310-2320
-
-
Srivastava, I.K.1
VanDorsten, K.2
Vojtech, L.3
-
70
-
-
0028244285
-
An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization
-
Mar;
-
Back NK, Smit L, De Jong JJ, et al. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 1994 Mar; 199 (2): 431-8
-
(1994)
Virology
, vol.199
, Issue.2
, pp. 431-438
-
-
Back, N.K.1
Smit, L.2
De Jong, J.J.3
-
71
-
-
9944225582
-
Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies
-
Jan 5;
-
Kang SM, Quan FS, Huang C, et al. Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Virology 2005 Jan 5; 331 (1): 20-32
-
(2005)
Virology
, vol.331
, Issue.1
, pp. 20-32
-
-
Kang, S.M.1
Quan, F.S.2
Huang, C.3
-
72
-
-
1842562419
-
N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies
-
Apr;
-
McCaffrey RA, Saunders C, Hensel M, et al. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J Virol 2004 Apr; 78 (7): 3279-95
-
(2004)
J Virol
, vol.78
, Issue.7
, pp. 3279-3295
-
-
McCaffrey, R.A.1
Saunders, C.2
Hensel, M.3
-
73
-
-
2942525411
-
HIV-1 acute infection Env glycomutants designed from 3D model: Effects on processing, antigenicity, and neutralization sensitivity
-
Jun 20;
-
Reynard F, FatmiA, Verrier B, et al. HIV-1 acute infection Env glycomutants designed from 3D model: effects on processing, antigenicity, and neutralization sensitivity. Virology 2004 Jun 20; 324 (1): 90-102
-
(2004)
Virology
, vol.324
, Issue.1
, pp. 90-102
-
-
Reynard, F.1
Fatmi, A.2
Verrier, B.3
-
74
-
-
0041920924
-
Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition
-
Sep 1;
-
Koch M, Pancera M, Kwong PD, et al. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 2003 Sep 1; 313 (2): 387-400
-
(2003)
Virology
, vol.313
, Issue.2
, pp. 387-400
-
-
Koch, M.1
Pancera, M.2
Kwong, P.D.3
-
75
-
-
52449127095
-
Levels of N-linked glycosylation on the V1 loop of HIV-1 Env proteins and their relationship to the antigenicity of Env from primary viral isolates
-
Jun;
-
Huang Z, Chou A, Tanguay J, et al. Levels of N-linked glycosylation on the V1 loop of HIV-1 Env proteins and their relationship to the antigenicity of Env from primary viral isolates. Curr HIV Res 2008 Jun; 6 (4): 296-305
-
(2008)
Curr HIV Res
, vol.6
, Issue.4
, pp. 296-305
-
-
Huang, Z.1
Chou, A.2
Tanguay, J.3
-
76
-
-
0038414622
-
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design
-
May;
-
Pantophlet R, Wilson IA, Burton DR. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J Virol 2003 May; 77 (10): 5889-901
-
(2003)
J Virol
, vol.77
, Issue.10
, pp. 5889-5901
-
-
Pantophlet, R.1
Wilson, I.A.2
Burton, D.R.3
-
77
-
-
22544471847
-
Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: Characterization and ligand binding analysis
-
Aug;
-
Pancera M, Lebowitz J, Schon A, et al. Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis. J Virol 2005 Aug; 79 (15): 9954-69
-
(2005)
J Virol
, vol.79
, Issue.15
, pp. 9954-9969
-
-
Pancera, M.1
Lebowitz, J.2
Schon, A.3
-
78
-
-
0033985999
-
A Recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure
-
Binley JM, Sanders RW, Clas B, et al. A Recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 2000; 74 (2): 627-43
-
(2000)
J Virol
, vol.74
, Issue.2
, pp. 627-643
-
-
Binley, J.M.1
Sanders, R.W.2
Clas, B.3
-
79
-
-
0036333661
-
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1
-
Sep;
-
Sanders RW, Vesanen M, Schuelke N, et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2002 Sep; 76 (17): 8875-89
-
(2002)
J Virol
, vol.76
, Issue.17
, pp. 8875-8889
-
-
Sanders, R.W.1
Vesanen, M.2
Schuelke, N.3
-
80
-
-
33947590277
-
A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120
-
Beddows S, Franti M, Dey AK,et al. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 2007; 360: 329-40
-
(2007)
Virology
, vol.360
, pp. 329-340
-
-
Beddows, S.1
Franti, M.2
Dey, A.K.3
-
81
-
-
54849437925
-
Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site
-
Burioni R, Mancini N, De Marco D, et al. Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site. PLoS ONE 2008; 3 (10): e3423
-
(2008)
PLoS ONE
, vol.3
, Issue.10
-
-
Burioni, R.1
Mancini, N.2
De Marco, D.3
-
82
-
-
33845439080
-
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector
-
Dec 15;
-
Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006 Dec 15; 194 (12): 1638-49
-
(2006)
J Infect Dis
, vol.194
, Issue.12
, pp. 1638-1649
-
-
Catanzaro, A.T.1
Koup, R.A.2
Roederer, M.3
-
83
-
-
33847121696
-
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: Negative results fail to trigger a phase 3 correlates trial
-
Feb 1;
-
Russell ND, Graham BS, Keefer MC, et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 2007 Feb 1; 44 (2): 203-12
-
(2007)
J Acquir Immune Defic Syndr
, vol.44
, Issue.2
, pp. 203-212
-
-
Russell, N.D.1
Graham, B.S.2
Keefer, M.C.3
-
84
-
-
34247201441
-
Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
-
May 16;
-
Catanzaro AT, Roederer M, Koup RA, et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007 May 16; 25 (20): 4085-92
-
(2007)
Vaccine
, vol.25
, Issue.20
, pp. 4085-4092
-
-
Catanzaro, A.T.1
Roederer, M.2
Koup, R.A.3
-
85
-
-
33845412550
-
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine
-
Dec 15;
-
Graham BS, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006 Dec 15; 194 (12): 1650-60
-
(2006)
J Infect Dis
, vol.194
, Issue.12
, pp. 1650-1660
-
-
Graham, B.S.1
Koup, R.A.2
Roederer, M.3
-
86
-
-
33745961311
-
Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults
-
Jul;
-
Mulligan MJ, Russell ND, Celum C, et al. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res Hum Retroviruses 2006 Jul; 22 (7): 678-83
-
(2006)
AIDS Res Hum Retroviruses
, vol.22
, Issue.7
, pp. 678-683
-
-
Mulligan, M.J.1
Russell, N.D.2
Celum, C.3
-
87
-
-
19944425960
-
Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins
-
Jan;
-
Mascola JR, Sambor A, Beaudry K, et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol 2005 Jan; 79 (2): 771-9
-
(2005)
J Virol
, vol.79
, Issue.2
, pp. 771-779
-
-
Mascola, J.R.1
Sambor, A.2
Beaudry, K.3
-
88
-
-
39149109930
-
Cross-subtype antibody and cellular immune responses induced byapolyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers
-
Wang S, Kennedy JS, West K, et al. Cross-subtype antibody and cellular immune responses induced byapolyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008; 26: 3947-57
-
(2008)
Vaccine
, vol.26
, pp. 3947-3957
-
-
Wang, S.1
Kennedy, J.S.2
West, K.3
-
89
-
-
0036500532
-
Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A
-
Mar 1;
-
Gupta K, Hudgens M, Corey L, et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 2002 Mar 1; 29 (3): 254-61
-
(2002)
J Acquir Immune Defic Syndr
, vol.29
, Issue.3
, pp. 254-261
-
-
Gupta, K.1
Hudgens, M.2
Corey, L.3
-
90
-
-
34848908400
-
A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01-AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost
-
Sep 1;
-
Thongcharoen P, Suriyanon V, Paris RM, et al. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01-AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 2007 Sep 1; 46 (1): 48-55
-
(2007)
J Acquir Immune Defic Syndr
, vol.46
, Issue.1
, pp. 48-55
-
-
Thongcharoen, P.1
Suriyanon, V.2
Paris, R.M.3
-
91
-
-
0033496071
-
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers
-
Aug;
-
Evans TG, Keefer MC, Weinhold KJ, et al. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999 Aug; 180 (2): 290-8
-
(1999)
J Infect Dis
, vol.180
, Issue.2
, pp. 290-298
-
-
Evans, T.G.1
Keefer, M.C.2
Weinhold, K.J.3
-
92
-
-
0035341521
-
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: A phase 2 study in higher- and lower-risk volunteers
-
May 1;
-
Belshe RB, Stevens C, Gorse GJ, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001 May 1; 183 (9): 1343-52
-
(2001)
J Infect Dis
, vol.183
, Issue.9
, pp. 1343-1352
-
-
Belshe, R.B.1
Stevens, C.2
Gorse, G.J.3
-
93
-
-
0036096976
-
Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization
-
Jun;
-
Chakrabarti BK, Kong WP, Wu BY, et al. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol 2002 Jun; 76 (11): 5357-68
-
(2002)
J Virol
, vol.76
, Issue.11
, pp. 5357-5368
-
-
Chakrabarti, B.K.1
Kong, W.P.2
Wu, B.Y.3
-
94
-
-
13944277994
-
Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys
-
Mar;
-
Seaman MS, Xu L, Beaudry K, et al. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 2005 Mar; 79 (5): 2956-63
-
(2005)
J Virol
, vol.79
, Issue.5
, pp. 2956-2963
-
-
Seaman, M.S.1
Xu, L.2
Beaudry, K.3
-
95
-
-
34548695901
-
Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multiclade HIV-1 envelope immunogens
-
Seaman MS, Leblanc DF, Grandpre LE, et al. Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multiclade HIV-1 envelope immunogens. Virology 2007; 367: 175-86
-
(2007)
Virology
, vol.367
, pp. 175-186
-
-
Seaman, M.S.1
Leblanc, D.F.2
Grandpre, L.E.3
-
96
-
-
0027284896
-
Gene inoculation generates immune responses against human immunodeficiency virus type 1
-
May 1;
-
Wang B, Ugen KE, Srikantan V, et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1993 May 1; 90 (9): 4156-60
-
(1993)
Proc Natl Acad Sci U S A
, vol.90
, Issue.9
, pp. 4156-4160
-
-
Wang, B.1
Ugen, K.E.2
Srikantan, V.3
-
97
-
-
0029037299
-
Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice
-
Lu S, Santoro JC, Fuller DH, et al. Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology 1995; 209 (1):147-54
-
(1995)
Virology
, vol.209
, Issue.1
, pp. 147-154
-
-
Lu, S.1
Santoro, J.C.2
Fuller, D.H.3
-
98
-
-
0030155046
-
In vivo protective anti-HIV immune responses in non-human primates through DNA immunization
-
Jun;
-
Boyer JD, Wang B, Ugen KE, et al. In vivo protective anti-HIV immune responses in non-human primates through DNA immunization. J Med Primatol 1996 Jun; 25 (3): 242-50
-
(1996)
J Med Primatol
, vol.25
, Issue.3
, pp. 242-250
-
-
Boyer, J.D.1
Wang, B.2
Ugen, K.E.3
-
99
-
-
0034703836
-
Induction of antigen-specific CD8+ T cells, T helper cells, and protective levelsofantibodyinhumans by particle-mediated administration of a hepatitis B virus DNA vaccine
-
Nov 22;
-
Roy MJ, Wu MS, Barr LJ, et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levelsofantibodyinhumans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000 Nov 22; 19 (7-8): 764-78
-
(2000)
Vaccine
, vol.19
, Issue.7-8
, pp. 764-778
-
-
Roy, M.J.1
Wu, M.S.2
Barr, L.J.3
-
100
-
-
0032538597
-
Induction of antigen-specific cytotoxic T lymphocytes in humansby a malaria DNA vaccine
-
Wang R, Doolan DL, Le TP, et al. Induction of antigen-specific cytotoxic T lymphocytes in humansby a malaria DNA vaccine. Science 1998; 282 (5388): 476-80
-
(1998)
Science
, vol.282
, Issue.5388
, pp. 476-480
-
-
Wang, R.1
Doolan2
DL, L.T.3
-
101
-
-
17444435761
-
Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients
-
May 2;
-
Calarota S, Bratt G, Nordlund S, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998 May 2; 351 (9112): 1320-5
-
(1998)
Lancet
, vol.351
, Issue.9112
, pp. 1320-1325
-
-
Calarota, S.1
Bratt, G.2
Nordlund, S.3
-
102
-
-
0005457558
-
First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response
-
Jul;
-
MacGregor RR, Boyer JD, Ugen KE,et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998 Jul; 178 (1): 92-100
-
(1998)
J Infect Dis
, vol.178
, Issue.1
, pp. 92-100
-
-
MacGregor, R.R.1
Boyer, J.D.2
Ugen, K.E.3
-
103
-
-
0032210747
-
DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans
-
Ugen KE, Nyland SB, Boyer JD, et al. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine 1998; 16 (19): 1818-21
-
(1998)
Vaccine
, vol.16
, Issue.19
, pp. 1818-1821
-
-
Ugen, K.E.1
Nyland, S.B.2
Boyer, J.D.3
-
104
-
-
0030917744
-
Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting
-
Apr 14;
-
Richmond JF, Mustafa F, Lu S, et al. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Virology 1997 Apr 14; 230 (2): 265-74
-
(1997)
Virology
, vol.230
, Issue.2
, pp. 265-274
-
-
Richmond, J.F.1
Mustafa, F.2
Lu, S.3
-
105
-
-
0031550774
-
HIV-1 Env glycoproteins from two series of primary isolates: Replication phenotype and immunogenicity
-
Mar 3;
-
Mustafa F, Richmond JF, Fernandez-Larsson R, et al. HIV-1 Env glycoproteins from two series of primary isolates: replication phenotype and immunogenicity. Virology 1997 Mar 3; 229 (1): 269-78
-
(1997)
Virology
, vol.229
, Issue.1
, pp. 269-278
-
-
Mustafa, F.1
Richmond, J.F.2
Fernandez-Larsson, R.3
-
106
-
-
13744254539
-
Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system
-
Feb;
-
Wang S, Chou TH, Sakhatskyy PV, et al. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol 2005 Feb; 79 (3): 1906-10
-
(2005)
J Virol
, vol.79
, Issue.3
, pp. 1906-1910
-
-
Wang, S.1
Chou, T.H.2
Sakhatskyy, P.V.3
-
107
-
-
0032920019
-
Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
-
Robinson HL, Montefiori DC, Johnson RP, et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 1999; 5 (5): 526-34
-
(1999)
Nat Med
, vol.5
, Issue.5
, pp. 526-534
-
-
Robinson, H.L.1
Montefiori, D.C.2
Johnson, R.P.3
-
108
-
-
23644440075
-
Electroporation for targeted gene transfer
-
Mar;
-
Heller LC, Ugen K, Heller R. Electroporation for targeted gene transfer. Expert Opin Drug Deliv 2005 Mar; 2 (2): 255-68
-
(2005)
Expert Opin Drug Deliv
, vol.2
, Issue.2
, pp. 255-268
-
-
Heller, L.C.1
Ugen, K.2
Heller, R.3
-
109
-
-
41549123253
-
The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods
-
Apr 16;
-
Wang S, Zhang C, Zhang L, et al. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 2008 Apr 16; 26 (17): 2100-10
-
(2008)
Vaccine
, vol.26
, Issue.17
, pp. 2100-2110
-
-
Wang, S.1
Zhang, C.2
Zhang, L.3
-
110
-
-
0035850961
-
Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device
-
Oct 12;
-
Aguiar JC, Hedstrom RC, Rogers WO, et al. Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device. Vaccine 2001 Oct 12; 20 (1-2): 275-80
-
(2001)
Vaccine
, vol.20
, Issue.1-2
, pp. 275-280
-
-
Aguiar, J.C.1
Hedstrom, R.C.2
Rogers, W.O.3
-
111
-
-
0033605223
-
Intradermal DNA immunization by using jet-injectors in mice and monkeys
-
Feb 26;
-
Haensler J, Verdelet C, Sanchez V, et al. Intradermal DNA immunization by using jet-injectors in mice and monkeys. Vaccine 1999 Feb 26; 17 (7-8): 628-38
-
(1999)
Vaccine
, vol.17
, Issue.7-8
, pp. 628-638
-
-
Haensler, J.1
Verdelet, C.2
Sanchez, V.3
-
112
-
-
10744223658
-
Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe
-
Sep 8;
-
Trimble C, Lin CT, Hung CF, et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003 Sep 8; 21 (25-26): 4036-42
-
(2003)
Vaccine
, vol.21
, Issue.25-26
, pp. 4036-4042
-
-
Trimble, C.1
Lin, C.T.2
Hung, C.F.3
-
113
-
-
1542358759
-
Microneedles for transdermal drug delivery
-
Mar 27;
-
Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 2004 Mar 27; 56 (5): 581-7
-
(2004)
Adv Drug Deliv Rev
, vol.56
, Issue.5
, pp. 581-587
-
-
Prausnitz, M.R.1
-
114
-
-
0034755765
-
Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein
-
Nov;
-
Deml L, Bojak A, Steck S, et al. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J Virol 2001 Nov; 75 (22): 10991-1001
-
(2001)
J Virol
, vol.75
, Issue.22
, pp. 10991-11001
-
-
Deml, L.1
Bojak, A.2
Steck, S.3
-
115
-
-
33646840487
-
Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine
-
May 22;
-
Wang S, Farfan-Arribas DJ, Shen S, et al. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine 2006 May 22; 24 (21): 4531-40
-
(2006)
Vaccine
, vol.24
, Issue.21
, pp. 4531-4540
-
-
Wang, S.1
Farfan-Arribas, D.J.2
Shen, S.3
-
116
-
-
0034056240
-
Increased expression and im-munogenicity of sequence-modified human immunodeficiency virus type 1 gag gene
-
zur Megede JZ, Chen MC, Doe B, et al. Increased expression and im-munogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J Virol 2000; 74 (6): 2628-35
-
(2000)
J Virol
, vol.74
, Issue.6
, pp. 2628-2635
-
-
zur Megede, J.Z.1
Chen, M.C.2
Doe, B.3
-
117
-
-
33751071573
-
Combination DNA plus protein HIV vaccines
-
Nov;
-
Lu S. Combination DNA plus protein HIV vaccines. Springer Semin Im-munopathol 2006 Nov; 28 (3): 255-65
-
(2006)
Springer Semin Im-munopathol
, vol.28
, Issue.3
, pp. 255-265
-
-
Lu, S.1
-
118
-
-
0031657986
-
Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting
-
Richmond JF, Lu S, Santoro JC, et al. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol 1998; 72 (11): 9092-100
-
(1998)
J Virol
, vol.72
, Issue.11
, pp. 9092-9100
-
-
Richmond, J.F.1
Lu, S.2
Santoro, J.C.3
-
119
-
-
0030872511
-
Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit
-
Jun;
-
Barnett SW, Rajasekar S, Legg H, et al. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine 1997 Jun; 15 (8): 869-73
-
(1997)
Vaccine
, vol.15
, Issue.8
, pp. 869-873
-
-
Barnett, S.W.1
Rajasekar, S.2
Legg, H.3
-
120
-
-
12644271200
-
Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
-
Aug 19;
-
Letvin NL, Montefiori DC, Yasutomi Y, et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A 1997 Aug 19; 94 (17): 9378-83
-
(1997)
Proc Natl Acad Sci U S A
, vol.94
, Issue.17
, pp. 9378-9383
-
-
Letvin, N.L.1
Montefiori, D.C.2
Yasutomi, Y.3
-
121
-
-
19944393561
-
Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1
-
Jun;
-
Wang S, Arthos J, Lawrence JM, et al. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol 2005 Jun; 79 (12): 7933-7
-
(2005)
J Virol
, vol.79
, Issue.12
, pp. 7933-7937
-
-
Wang, S.1
Arthos, J.2
Lawrence, J.M.3
-
122
-
-
33746651142
-
-
Wang S,Pal R, Mascola JR, et al. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 2006 Jun 20; 350 (1): 34-47
-
Wang S,Pal R, Mascola JR, et al. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 2006 Jun 20; 350 (1): 34-47
-
-
-
-
123
-
-
33745496632
-
Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype
-
May 10;
-
Pal R, Wang S, Kalyanaraman VS, et al. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 2006 May 10; 348 (2): 341-53
-
(2006)
Virology
, vol.348
, Issue.2
, pp. 341-353
-
-
Pal, R.1
Wang, S.2
Kalyanaraman, V.S.3
-
124
-
-
0036099015
-
DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus
-
Feb;
-
Rasmussen RA, Hofmann-Lehman R, Montefiori DC, et al. DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus. J Med Primatol 2002 Feb; 31 (1): 40-60
-
(2002)
J Med Primatol
, vol.31
, Issue.1
, pp. 40-60
-
-
Rasmussen, R.A.1
Hofmann-Lehman, R.2
Montefiori, D.C.3
-
125
-
-
33845207796
-
Durable HIV-1 antibody and T-cell responses elicitedby an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers
-
Goepfert PA, Tomaras GD, Horton H, et al. Durable HIV-1 antibody and T-cell responses elicitedby an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 2007; 25: 510-8
-
(2007)
Vaccine
, vol.25
, pp. 510-518
-
-
Goepfert, P.A.1
Tomaras, G.D.2
Horton, H.3
-
126
-
-
48449105674
-
The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers
-
Aug 18;
-
Kennedy JS, Co M, Green S, et al. The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine 2008 Aug 18; 26 (35): 4420-4
-
(2008)
Vaccine
, vol.26
, Issue.35
, pp. 4420-4424
-
-
Kennedy, J.S.1
Co, M.2
Green, S.3
-
127
-
-
47749129289
-
Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination
-
Aug;
-
Vaine M, Wang S, Crooks ET, et al. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol 2008 Aug; 82 (15): 7369-78
-
(2008)
J Virol
, vol.82
, Issue.15
, pp. 7369-7378
-
-
Vaine, M.1
Wang, S.2
Crooks, E.T.3
-
128
-
-
34948854718
-
Broad HIV-1 neutralization mediated by CD4-binding site antibodies
-
Sep;
-
Li Y, Migueles SA, Welcher B, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007 Sep; 13 (9): 1032-4
-
(2007)
Nat Med
, vol.13
, Issue.9
, pp. 1032-1034
-
-
Li, Y.1
Migueles, S.A.2
Welcher, B.3
|